Page last updated: 2024-10-28

guanfacine and Benign Psychomotor Epilepsy, Childhood

guanfacine has been researched along with Benign Psychomotor Epilepsy, Childhood in 1 studies

Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Swartz, BE	1
Kovalik, E	1
Thomas, K	1
Torgersen, D	1
Mandelkern, MA	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885]				16 participants (Actual)	Interventional	2008-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Inferior Parietal Lobule

"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Intervention	percent change in saline signal (Mean)
Guanfacine	-0.17
Placebo	-0.094

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Middle Frontal Gyrus

Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Intervention	percent change in saline signal (Mean)
Guanfacine	-0.1
Placebo	0.052

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Superior Frontal Gyrus

Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Intervention	percent change in saline signal (Mean)
Guanfacine	-0.134
Placebo	-0.086

Trials

1 trial available for guanfacine and Benign Psychomotor Epilepsy, Childhood

Article	Year
The effects of an alpha-2 adrenergic agonist, guanfacine, on rCBF in human cortex in normal controls and subjects with focal epilepsy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2000, Volume: 23, Issue:3 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Blood Pressure; Cerebral Cor	2000